Savaria (SIS) investor relations material

Executive summary

• Achieved record quarterly revenue of CAD 246 million (USD 245.8M), up 8.4% year-over-year, with balanced growth in both patient care and accessibility segments.

• Adjusted EBITDA reached CAD 51.8 million (margin 21.1%), reflecting operational improvements and the Savaria One program.

• Growth initiatives and acquisitions, including Baxter Elevator in Texas and Vipal S.p.A. in Italy, are expanding geographic and product reach.

• Strong liquidity position with CAD 333 million available for capital allocation and a net debt-to-EBITDA ratio of 0.7.

• Long-term ambition to grow revenue at 12% annually and maintain EBITDA margins above 20% through 2030.

Financial highlights

• Q2 2026 revenue grew 8.4% year-over-year to CAD 245.8 million, with 6.6% organic growth and 0.8% from acquisitions.

• Adjusted EBITDA margin improved to 21.1%, up 50 basis points from the prior year.

• Gross margin expanded to 39.6%, a 60 basis point increase year-over-year.

• Net earnings rose 54.4% to CAD 25.2 million (CAD 0.34 per diluted share).

• Cash flow from operating activities increased to CAD 33.3 million, up from CAD 30.3 million in Q2 2025.

Outlook and guidance

• Targeting annual revenue growth of approximately 12% through 2030, aiming for CAD 1.6 billion in sales and EBITDA over CAD 220 million by 2030.

• Plans to maintain adjusted EBITDA margins of at least 20% and increase adjusted EBITDA per share to ~$4.25 by 2030.

• Ongoing focus on organic growth, margin expansion, and strategic acquisitions.